The clinical outcomes of COVID-19 infection in patients with a history of thyroid cancer: A nationwide study.
COVID-19
mortality
radioactive iodine therapy
thyroid cancer
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
03
04
2021
received:
18
02
2021
accepted:
15
04
2021
pubmed:
20
4
2021
medline:
1
10
2021
entrez:
19
4
2021
Statut:
ppublish
Résumé
There are scarce published data in differentiated thyroid cancer patients about new coronavirus disease 2019 (COVID-19) disease outcomes and mortality. Here, we evaluated COVID-19 infection outcomes and mortality in thyroid cancer patients with COVID-19 infection. We included a cohort of patients with thyroid cancer with PCR-confirmed COVID-19 disease from 11 March to 30 May 2020 from the Turkish Ministry of Health database in our nationwide, retrospective study. We compared the mortality and morbidity of COVID patients with or without thyroid cancer. Univariate and multivariate analyses were used to assess the independent factors for mortality, length of hospital stay and intensive care unit (ICU) admission and mechanical ventilation. We also analysed the effect of radioiodine treatment on severity and death rate of COVID-19 disease. We evaluated 388 COVID-19 patients with thyroid cancer [median age: 54 years, interquartile range (IQR) 18 years, males: 23%] and age and gender-matched 388 COVID-19 patients without thyroid cancer. Patients with thyroid cancer had a similar mortality ratio compared with the non-cancer group. Among patients with thyroid cancer, age, presence of diabetes mellitus, asthma/COPD, heart failure, chronic kidney disease, prior coronary artery disease, RAS blocker usage and low lymphocyte count were associated with mortality. Radioactive iodine (RAI) treatment and cumulative radioactive iodine dosage did not negatively affect the severity and mortality of COVID-19 disease in our patient group. Our study indicated that history of thyroid cancer did not have an increased risk of mortality or morbidity in COVID-19 disease. Besides, RAI therapy history and doses of radioactive iodine did not affect mortality or outcome.
Sections du résumé
BACKGROUND
There are scarce published data in differentiated thyroid cancer patients about new coronavirus disease 2019 (COVID-19) disease outcomes and mortality. Here, we evaluated COVID-19 infection outcomes and mortality in thyroid cancer patients with COVID-19 infection.
DESIGN AND METHODS
We included a cohort of patients with thyroid cancer with PCR-confirmed COVID-19 disease from 11 March to 30 May 2020 from the Turkish Ministry of Health database in our nationwide, retrospective study. We compared the mortality and morbidity of COVID patients with or without thyroid cancer. Univariate and multivariate analyses were used to assess the independent factors for mortality, length of hospital stay and intensive care unit (ICU) admission and mechanical ventilation. We also analysed the effect of radioiodine treatment on severity and death rate of COVID-19 disease.
RESULTS
We evaluated 388 COVID-19 patients with thyroid cancer [median age: 54 years, interquartile range (IQR) 18 years, males: 23%] and age and gender-matched 388 COVID-19 patients without thyroid cancer. Patients with thyroid cancer had a similar mortality ratio compared with the non-cancer group. Among patients with thyroid cancer, age, presence of diabetes mellitus, asthma/COPD, heart failure, chronic kidney disease, prior coronary artery disease, RAS blocker usage and low lymphocyte count were associated with mortality. Radioactive iodine (RAI) treatment and cumulative radioactive iodine dosage did not negatively affect the severity and mortality of COVID-19 disease in our patient group.
CONCLUSIONS
Our study indicated that history of thyroid cancer did not have an increased risk of mortality or morbidity in COVID-19 disease. Besides, RAI therapy history and doses of radioactive iodine did not affect mortality or outcome.
Identifiants
pubmed: 33872399
doi: 10.1111/cen.14486
pmc: PMC8251412
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
628-637Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Lancet Oncol. 2020 Aug;21(8):1035-1044
pubmed: 32702311
Curr Cardiol Rep. 2020 Oct 10;22(12):171
pubmed: 33040241
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Thyroid. 2013 May;23(5):609-16
pubmed: 23153322
Thyroid. 2013 Jul;23(7):885-91
pubmed: 23517343
J Endocrinol. 2017 Feb;232(2):R67-R81
pubmed: 27852725
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
J Clin Endocrinol Metab. 2015 Oct;100(10):3911-7
pubmed: 26262436
Immunol Lett. 2017 Apr;184:76-83
pubmed: 28216261
Nat Med. 2020 Aug;26(8):1218-1223
pubmed: 32581323
Clin Endocrinol (Oxf). 2021 Oct;95(4):628-637
pubmed: 33872399
Front Oncol. 2020 Oct 21;10:570130
pubmed: 33194660
Eur J Endocrinol. 2020 Jul;183(1):G41-G48
pubmed: 32438345
Acta Oncol. 1990;29(8):1035-9
pubmed: 2278724
J Natl Compr Canc Netw. 2010 Nov;8(11):1277-86; quiz 1287
pubmed: 21081784
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
PLoS One. 2020 Dec 15;15(12):e0243600
pubmed: 33320875
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
Endocr Relat Cancer. 2020 Nov;27(11):R407-R416
pubmed: 32810844
Ann Oncol. 2020 Aug;31(8):1088-1089
pubmed: 32330541